Results 31 to 40 of about 1,341 (168)
Teprotumumab: a disease modifying treatment for graves’ orbitopathy
Thyroid Research, 2020 Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled ...
Michelle Ting, Daniel G. Ezra
doaj +1 more source
Thyroid dermopathy responds to teprotumumab therapy
Endocrinology, Diabetes & Metabolism Case Reports, 2022 Thyroid dermopathy is an uncommon manifestation of thyroid disease that impairs the quality of life in certain cases. Currently, the available treatments offer limited results and a chance of recurrence.
Ricaurte Crespo-Trevino +6 more
doaj +1 more source
Treating Thyroid Associated Ophthalmopathy in Pediatric Patients
Frontiers in Endocrinology, 2022 Thyroid associated ophthalmopathy (TAO) is a common extra-thyroid clinical manifestation of Graves’ disease. It is an inflammatory disease of the eye and orbital tissues.
Tianyu Dong, Zhujun Fu, Xu Wang
doaj +1 more source
Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study
American Journal of Ophthalmology Case Reports, 2021 Purpose: To study post-interventional findings in patients with dysthyroid optic neuropathy (DON) treated with teprotumumab. Observations: In this multicenter observational Case series, patients with DON were treated with teprotumumab, an insulin-like ...
Connie M. Sears +7 more
doaj +1 more source
, 2023 Clinical and Translational Medicine, Volume 13, Issue 4, April 2023.
Jing Hu +13 more
wiley +1 more source
, 2021 Thyroid eye disease (TED) is a vision-threatening and debilitating condition that until very recently had no Food and Drug Administration (FDA)-approved medical therapies. Teprotumumab has recently been approved to treat TED.
Fleming, James +19 more
core +1 more source
Teprotumumab Treats Sight-Threatening Thyroid Eye Disease
, 2021 We report a unique case of dysthyroid optic neuropathy (DON) treated primarily with teprotumumab and corticosteroids. The patient showed rapid improvement in visual acuity, visual field loss, color vision, and reduction in exophthalmos.
Michael Lopez Lopez; Dilip Thomas; Ciera Thomas
core
, 2023 Teprotumumab is a novel IGF-1R inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation.
Lu T.J. (14801866) +5 more
core +1 more source
Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease
, 2022 Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients in phase 2 and 3 (OPTIC) trials.1,2 OPTIC proptosis non ...
Prem S. Subramanian; Saba Sile; Robert Holt; Raymond Douglas
core +2 more sources
Emerging therapies in the medical management of thyroid eye disease
Frontiers in Ophthalmology, 2023 IntroductionThyroid eye disease (TED) is an immune-mediated disorder associated with a heterogenous array of manifestations that may unfavorably impact vision and quality of life.
Alisha Kamboj +3 more
doaj +1 more source